ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror.
During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims.
['Kelleni|Mina T|MT|http://orcid.org/0000-0001-6290-6025']
D057911:Angiotensin Receptor Antagonists D000806:Angiotensin-Converting Enzyme Inhibitors D000894:Anti-Inflammatory Agents, Non-Steroidal D000086382:COVID-19 D018352:Coronavirus Infections D006801:Humans D007052:Ibuprofen D058873:Pandemics D011024:Pneumonia, Viral
Aceis Arbs Ibuprofen COVID-19 SARS CoV-2